DK1218751T3 - Cöliakidiagnose under anvendelse af et gliadinepitop - Google Patents

Cöliakidiagnose under anvendelse af et gliadinepitop

Info

Publication number
DK1218751T3
DK1218751T3 DK00964460T DK00964460T DK1218751T3 DK 1218751 T3 DK1218751 T3 DK 1218751T3 DK 00964460 T DK00964460 T DK 00964460T DK 00964460 T DK00964460 T DK 00964460T DK 1218751 T3 DK1218751 T3 DK 1218751T3
Authority
DK
Denmark
Prior art keywords
epitope
seq
gliadin
coeliac disease
sequence
Prior art date
Application number
DK00964460T
Other languages
English (en)
Inventor
Robert Paul Molecular Anderson
Adrian Vivian Sinton Well Hill
Derek Parry Gastroenter Jewell
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of DK1218751T3 publication Critical patent/DK1218751T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
DK00964460T 1999-10-01 2000-10-02 Cöliakidiagnose under anvendelse af et gliadinepitop DK1218751T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923306.6A GB9923306D0 (en) 1999-10-01 1999-10-01 Diagnostic and therapeutic epitope, and transgenic plant

Publications (1)

Publication Number Publication Date
DK1218751T3 true DK1218751T3 (da) 2006-07-03

Family

ID=10861989

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00964460T DK1218751T3 (da) 1999-10-01 2000-10-02 Cöliakidiagnose under anvendelse af et gliadinepitop
DK05027922T DK1672368T3 (da) 1999-10-01 2000-10-02 Diagnostisk og terapeutisk epitop

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05027922T DK1672368T3 (da) 1999-10-01 2000-10-02 Diagnostisk og terapeutisk epitop

Country Status (14)

Country Link
US (5) US7144569B1 (da)
EP (2) EP1218751B1 (da)
JP (4) JP4932112B2 (da)
AT (2) ATE449965T1 (da)
AU (1) AU782262B2 (da)
CA (1) CA2386089C (da)
CY (2) CY1105282T1 (da)
DE (2) DE60026332T2 (da)
DK (2) DK1218751T3 (da)
ES (2) ES2335895T3 (da)
GB (1) GB9923306D0 (da)
MX (1) MXPA02003295A (da)
PT (2) PT1672368E (da)
WO (1) WO2001025793A2 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
ES2361993T5 (es) 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
WO2004045392A2 (en) 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
EP1711604B1 (en) * 2004-01-09 2011-10-05 Ottawa Health Research Institute Diabetogenic epitopes
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
CN102430111B (zh) 2004-04-28 2018-03-02 英国技术集团国际有限公司 与腹部疾病有关的表位
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP1612558A1 (en) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
EP1993593B1 (en) * 2006-03-15 2015-08-26 Isocell S.A. Pharmaceutical compositions comprising sods and gliadin based peptide fragments
US7576040B2 (en) * 2007-01-11 2009-08-18 Halliburton Energy Services, Inc. Cement compositions comprising humic acid grafted fluid loss control additives
EP2136833B1 (en) 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
JP5855828B2 (ja) 2007-08-13 2016-02-09 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 低レベルのホルデインを有するオオムギ
MX346450B (es) * 2008-11-30 2017-03-17 Immusant Inc * Composiciones y métodos para el tratamiento de la enfermedad celíaca.
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2666017B1 (en) 2011-01-20 2018-10-03 Cyrex Laboratories, LLC Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
US20140037661A1 (en) * 2011-02-08 2014-02-06 Phadia Ab Wheat Antigens and Peptides for Diagnosis of Wheat Induced Hypersensitivity
US9629848B2 (en) 2011-05-26 2017-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
WO2014179202A1 (en) * 2013-05-02 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
WO2014182897A2 (en) * 2013-05-08 2014-11-13 Jm Biologicals Compositions and methods for the production of gluten free food products
EP2997368B1 (en) 2013-05-14 2019-01-02 Oslo Universitetssykehus HF Detection of gluten-specific t-cells
EP3008161A4 (en) 2013-06-13 2017-02-22 Commonwealth Scientific and Industrial Research Organisation Barley with very low levels of hordeins
CA2923822A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR20240154672A (ko) 2014-02-21 2024-10-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3134730A4 (en) * 2014-04-24 2018-01-17 Immusant Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
WO2016081869A2 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
DE102015204012A1 (de) 2015-03-05 2016-09-08 Clariant International Ltd. SCR-Katalysator mit verbesserter Haftung
US9820957B2 (en) 2016-03-24 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmunity
CA3035484A1 (en) * 2016-09-01 2018-03-08 Cellectis Methods for altering amino acid content in plants
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
SG11202011078VA (en) 2018-05-09 2020-12-30 Univ Chicago Compositions and methods concerning immune tolerance
CN110128549B (zh) * 2019-05-27 2021-07-06 深圳市亚辉龙生物科技股份有限公司 脱酰胺基麦胶蛋白多肽重组抗原、重组抗原表达基因、重组表达载体及其制备方法和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459355A (en) 1982-07-12 1984-07-10 International Paper Company Method for transforming plant cells
US4536475A (en) 1982-10-05 1985-08-20 Phytogen Plant vector
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
JPS6047683A (ja) 1983-08-24 1985-03-15 Kirin Brewery Co Ltd プロモ−タ−
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4943674A (en) * 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
DK162399C (da) 1986-01-28 1992-03-23 Danisco Fremgangsmaade til ekspression af gener i baelgplanteceller, dna-fragment, rekombineret dna-fragment samt plasmid til brug ved udoevelsen af fremgangsmaaden
DE3765449D1 (de) 1986-03-11 1990-11-15 Plant Genetic Systems Nv Durch gentechnologie erhaltene und gegen glutaminsynthetase-inhibitoren resistente pflanzenzellen.
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5177010A (en) 1986-06-30 1993-01-05 University Of Toledo Process for transforming corn and the products thereof
US5187073A (en) 1986-06-30 1993-02-16 The University Of Toledo Process for transforming gramineae and the products thereof
NZ221259A (en) 1986-07-31 1990-05-28 Calgene Inc Seed specific transcriptional regulation
EP0267159A3 (de) 1986-11-07 1990-05-02 Ciba-Geigy Ag Verfahren zur genetischen Modifikation monokotyler Pflanzen
US4866247A (en) 1986-12-11 1989-09-12 The Lincoln Electric Company Apparatus and method of short circuiting arc welding
US4971908A (en) 1987-05-26 1990-11-20 Monsanto Company Glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate synthase
US5356799A (en) * 1988-02-03 1994-10-18 Pioneer Hi-Bred International, Inc. Antisense gene systems of pollination control for hybrid seed production
US5371014A (en) 1988-02-12 1994-12-06 Daicel Chemical Industries, Ltd. Process for the production of optically active 2-hydroxy acid esters using microbes to reduce the 2-oxo precursor
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5250515A (en) * 1988-04-11 1993-10-05 Monsanto Company Method for improving the efficacy of insect toxins
US5565346A (en) 1988-07-27 1996-10-15 Calgene, Inc. Transformation and regeneration system for legumes
US5428146A (en) * 1988-11-07 1995-06-27 Max-Planck-Gesellschaft Zur Forderung Wound-stimulated DNA-sequence from solanum tuberosum and its use
US5110732A (en) * 1989-03-14 1992-05-05 The Rockefeller University Selective gene expression in plants
US5086169A (en) 1989-04-20 1992-02-04 The Research Foundation Of State University Of New York Isolated pollen-specific promoter of corn
US5629183A (en) * 1989-05-08 1997-05-13 The United States Of America As Represented By The Secretary Of Agriculture Plant transformation by gene transfer into pollen
US5097025A (en) 1989-08-01 1992-03-17 The Rockefeller University Plant promoters
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
HU218465B (hu) 1989-08-09 2000-09-28 Dekalb Genetics Corporation Eljárások és kompozíciók stabilan transzformált, termő egyszikű növények és sejtjeik előállítására
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
CA2071879C (en) 1989-10-27 2007-05-15 Stephen F. Heinemann Glutamate receptor compositions and methods
US5589583A (en) 1990-01-11 1996-12-31 Monsanto Company Plant promoter
JP3209744B2 (ja) 1990-01-22 2001-09-17 デカルブ・ジェネティクス・コーポレーション 結実能力のある遺伝子変換コーン
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
EP0442174A1 (en) 1990-02-13 1991-08-21 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
US5618988A (en) * 1990-03-02 1997-04-08 Amoco Corporation Enhanced carotenoid accumulation in storage organs of genetically engineered plants
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5187267A (en) 1990-06-19 1993-02-16 Calgene, Inc. Plant proteins, promoters, coding sequences and use
EP0536330B1 (en) 1990-06-25 2002-02-27 Monsanto Technology LLC Glyphosate tolerant plants
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
NZ239977A (en) 1990-11-14 1993-08-26 Pioneer Hi Bred Int Transforming plants by the use of agrobacterium
EP0559742A1 (en) 1990-11-26 1993-09-15 E.I. Du Pont De Nemours And Company Herbicidal oxazine ethers
US5459252A (en) 1991-01-31 1995-10-17 North Carolina State University Root specific gene promoter
US5589610A (en) 1991-02-07 1996-12-31 Plant Genetic Systems, N.V. Stamen-specific promoters from corn
IL101508A0 (en) 1991-04-08 1992-12-30 Rhone Poulenc Agrochimie Chimeric plant genes based on upstream regulatory elements of helianthinin
DE69232132T3 (de) 1991-05-15 2008-08-14 Monsanto Technology Llc. Verfahren zur schöpfung einer transformierten reispflanze
AU2515592A (en) 1991-08-23 1993-03-16 University Of Florida A novel method for the production of transgenic plants
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
WO1994010307A1 (en) 1992-10-29 1994-05-11 Medical Research Council Transcription factor dp-1
US5389226A (en) 1992-12-17 1995-02-14 Amorphous Technologies International, Inc. Electrodeposition of nickel-tungsten amorphous and microcrystalline coatings
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1994025613A1 (en) 1993-05-03 1994-11-10 Cornell Research Foundation, Inc. Isolated dna elements that direct pistil-specific and anther-specific gene expression and methods of using same
US5670349A (en) * 1993-08-02 1997-09-23 Virginia Tech Intellectual Properties, Inc. HMG2 promoter expression system and post-harvest production of gene products in plants and plant cell cultures
DE69433809T2 (de) 1993-09-03 2005-06-16 Japan Tobacco Inc. Verfahren zur transformation von monocotyledonen mittels des schildes von unreifen embryonen
WO1995019030A1 (en) * 1994-01-05 1995-07-13 Pois, Inc. Apparatus and method for a personal onboard information system
US5495007A (en) 1994-04-29 1996-02-27 Thompson; Gary A. Phloem-specific promoter
US5459007A (en) * 1994-05-26 1995-10-17 Xerox Corporation Liquid developer compositions with block copolymers
US5633363A (en) * 1994-06-03 1997-05-27 Iowa State University, Research Foundation In Root preferential promoter
US5646333A (en) 1994-09-02 1997-07-08 Drexel University Plant promoter useful for directing the expression of foreign proteins to the plant epidermis
HUT76355A (en) 1995-11-24 1997-08-28 Bay Zoltan Alkalmazott Kutatas Plant gene-expression vector family based on dna fragments regulating alfalfa h3 histon gene variant (ms h3g1)
US6036983A (en) * 1996-05-20 2000-03-14 Novo Nordisk A/S Method of obtaining protein hydrolysates
CA2257972A1 (en) 1996-06-13 1997-12-18 Consejo Superior De Investigaciones Cientificas Plant proteins
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US5977436A (en) 1997-04-09 1999-11-02 Rhone Poulenc Agrochimie Oleosin 5' regulatory region for the modification of plant seed lipid composition
US5959175A (en) 1997-04-09 1999-09-28 Thomas; Terry L. Sunflower albumin 5' regulatory region for the modification of plant seed lipid composition
ES2132025B1 (es) 1997-06-12 2000-12-01 Consejo Superior Investigacion Proteinas urag de las plantas.
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof
US6100450A (en) 1997-10-22 2000-08-08 Rhone-Poulenc Agrochimie Seed specific promoters based on arabidopsis genes
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
AU3478599A (en) 1998-04-09 1999-11-01 E.I. Du Pont De Nemours And Company Cell cycle regulatory proteins
AU3828099A (en) 1998-05-08 1999-11-29 Consejo Superior De Investigaciones Cientificas Transgenic plant cells expressing a recombinant plant e2f peptide
WO2000047614A1 (en) 1999-02-12 2000-08-17 Pioneer Hi-Bred International, Inc. Transgenic plants with modified expression of the dp protein
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
MXPA03009313A (es) 2001-04-12 2004-11-12 Academish Ziekenhuis Leiden Metodos y medios para uso de receptores de celulas t restringidos por hla-dq y peptidos derivados de prolamina unidos a hla-dq.
DE60221700T2 (de) * 2001-12-11 2008-04-30 Tagsys S.A. Systeme zum sicheren markieren von daten
EP1332760A1 (en) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
ES2361993T5 (es) * 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
WO2004045392A2 (en) * 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US7144567B2 (en) * 2002-12-16 2006-12-05 Erling Jim Andersen Renewable energy carrier system and method

Also Published As

Publication number Publication date
DE60043402D1 (de) 2010-01-07
CA2386089A1 (en) 2001-04-12
PT1218751E (pt) 2006-06-30
JP2010263898A (ja) 2010-11-25
US8329144B2 (en) 2012-12-11
JP4932112B2 (ja) 2012-05-16
JP2003511670A (ja) 2003-03-25
GB9923306D0 (en) 1999-12-08
WO2001025793A2 (en) 2001-04-12
US20080175971A1 (en) 2008-07-24
EP1672368B1 (en) 2009-11-25
DE60026332T2 (de) 2006-08-10
US7888460B2 (en) 2011-02-15
JP6139154B2 (ja) 2017-05-31
CY1105282T1 (el) 2010-03-03
PT1672368E (pt) 2010-01-20
DK1672368T3 (da) 2010-01-04
US20130318648A1 (en) 2013-11-28
US7144569B1 (en) 2006-12-05
ATE319091T1 (de) 2006-03-15
US20180057547A1 (en) 2018-03-01
AU7539400A (en) 2001-05-10
EP1218751B1 (en) 2006-03-01
CA2386089C (en) 2016-06-21
EP1672368A1 (en) 2006-06-21
HK1088068A1 (en) 2006-10-27
US20110044912A2 (en) 2011-02-24
JP5371890B2 (ja) 2013-12-18
DE60026332D1 (de) 2006-04-27
ATE449965T1 (de) 2009-12-15
WO2001025793A3 (en) 2001-08-23
AU782262B2 (en) 2005-07-14
MXPA02003295A (es) 2002-09-02
JP2013126991A (ja) 2013-06-27
ES2256042T3 (es) 2006-07-16
CY1109837T1 (el) 2014-09-10
US20090269285A1 (en) 2009-10-29
JP2016164169A (ja) 2016-09-08
EP1218751A2 (en) 2002-07-03
ES2335895T3 (es) 2010-04-06

Similar Documents

Publication Publication Date Title
DK1672368T3 (da) Diagnostisk og terapeutisk epitop
Fuchs et al. The expression of keratin genes in epidermis and cultured epidermal cells
Sanger The chemistry of insulin
Givol et al. The C-terminal peptide of the heavy chain of the rabbit immunoglobulin IgG
Bulinski et al. Peptide antibody specific for the amino terminus of skeletal muscle alpha-actin.
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
GB9722320D0 (en) Human cell cycle checkpoint proteins
Henschen et al. Sequence homology between γ-chain and β-chain in human fibrin
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
JPS6420095A (en) Polypeptide having anti-blood coagulating action
Chiou A novel crystallin from octopus lens
EP1132402A4 (en) PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY
ATE431414T1 (de) Transportpeptide abgeleitet von erns protein
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
CA2452593A1 (en) Triple polypeptide complexes
EP1065214A4 (en) NEW, PHYSIOLOGICALLY ACTIVE PEPTIDES AND THEIR USE.
NO178504C (no) Fr.måte for fr.stilling av minaktivin,DNA-molekyl,gen,vert,prober,preparat som omfatter prober,reagens for lokalisering og defini. av grenser for tumor i histologiske pröver,samt anvendelse av DNA-molekyl,minaktivin og preparat
NZ233328A (en) Polypeptides produced by hepatocytes infected with p. falciparum; nucleic acid probes
DE69017352D1 (de) An HIV relatierte Peptide.
WO1995021916A3 (en) Pp32: a newly identified cd45-associated protein
ES2059431T3 (es) Mutantes de la creatinamidinohidrolasa estables.
ATE260339T1 (de) Antikörper gegen menschliches restrictin
Sanger Les Prix Nobel en 1958
WO2001074854A3 (en) 32449, a putative human transporter and uses thereof
WO2002024913A3 (en) 32612, a novel human peptide transporter and uses therefor